Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07369024 · ClinicalTrials.gov registry record · Phase 2
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
A Phase 2 study of Sickle Cell Disease and Pain Management, sponsored by Mohsen Saidinejad.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT07369024: Recruiting Phase 2 study of Sickle Cell Disease and Pain Management, sponsored by Mohsen Saidinejad.
NCT07369024 is a Phase 2 study of Sickle Cell Disease and Pain Management that is actively recruiting participants, run by Mohsen Saidinejad. The registered enrollment target is 120 participants, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07369024, a Phase 2 study of Sickle Cell Disease and Pain Management, is actively recruiting participants, sponsored by Mohsen Saidinejad.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to see if ketamine is effective and safe in treating children and young adults with sickle cell disease experiencing sickle cell related pain. In this study, we will compare the outcomes (such as pain scores) in persons who receive standard of care pain medicine (an opioid such as morphine) plus a low dose (amount) of ketamine to those who receive only standard of care pain medicine.
Primary Outcome
Cumulative morphine-mg equivalent per kilogram (MME/kg) of opioid medication needed to achieve a pain score of ≤ 5
Conditions Studied
Interventions
- DRUG Sub-dissociative Ketamine Infusion
- DRUG Normal Saline Placebo Infusion
Study Locations (1)
California
- Harbor UCLA Medical Center - Torrance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2026-04-01 |
| Est. Completion | 2028-04-30 |
| Phase | Phase 2 |
What NCT07369024 shows while recruiting
NCT07369024 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (59% lower).
The record links to 5 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 2 interventions - of which Sub-dissociative Ketamine Infusion is the first listed.
NCT07369024 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07369024 about?
NCT07369024 is a clinical study titled "Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults". The purpose of this research is to see if ketamine is effective and safe in treating children and young adults with sickle cell disease experiencing sickle cell related pain. In this study, we will compare the outcomes (such as pain scores) in persons who receive standard of care pain medicine (an o...
What is the current status of trial NCT07369024?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2026-04-01. Estimated completion is 2028-04-30.
What conditions does trial NCT07369024 study?
This clinical trial studies the following conditions: Sickle Cell Disease, Pain Management, Vaso-Occlusive Pain Episode in Sickle Cell Disease, Ketamine Infusion, Vaso-Occlusive Crises.
What interventions are being tested in trial NCT07369024?
The interventions under investigation include: Sub-dissociative Ketamine Infusion (DRUG), Normal Saline Placebo Infusion (DRUG).
Who is sponsoring clinical trial NCT07369024?
This trial is sponsored by Mohsen Saidinejad, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07369024 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07369024's enrollment target sits among peer trials
120 51st of 213 higher than 159 of 213 other Sickle Cell Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET
RECRUITING · Phase 2
-
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
RECRUITING · Phase 2
-
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
RECRUITING · Phase 2
-
A Phase 2/3 Study in Adult and Adolescent Participants With SCD
RECRUITING · Phase 2
-
Allo HSCT for High Risk Hemoglobinopathies
RECRUITING · Phase 2
-
Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI